Novavax Statistics
Novavax (NVV1) Stock Statistics & Valuation Metrics
Total Valuation
Novavax has a market cap or net worth of EUR 1.52B. The enterprise value is EUR 1.46B.
- Market Cap
- EUR 1.52B
- Enterprise Value
- EUR 1.46B
Share Statistics
Novavax has 165,009,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 165,009,000
- Owned by Insiders
- 0.58%
- Owned by Institutions
- 48.07%
Financial Efficiency
Novavax’s return on equity (ROE) is -3.45 and return on invested capital (ROIC) is 78.00%.
- Return on Equity (ROE)
- -3.45
- Return on Assets (ROA)
- 0.37
- Return on Invested Capital (ROIC)
- 78.00%
- Return on Capital Employed (ROCE)
- 0.79
- Revenue Per Employee
- 1.50M
- Profits Per Employee
- 587.85K
- Employee Count
- 749
- Asset Turnover
- 0.95
- Inventory Turnover
- 6.16
Valuation Ratios
The current PE Ratio of Novavax is -21.70. Novavax’s PEG ratio is 0.33.
- PE Ratio
- -21.70
- PS Ratio
- 4.00
- PB Ratio
- -7.59
- Price to FCF
- -6.68
- Price to Operating Cash Flow
- -6.81
- PEG Ratio
- 0.33
Income Statement
In the last 12 months, Novavax had revenue of 1.12B and earned 440.30M in profits. Earnings per share was 2.72.
- Revenue
- 1.12B
- Gross Profit
- 1.05B
- Operating Income
- 563.27M
- Pretax Income
- 442.17M
- Net Income
- 440.30M
- EBITDA
- 492.33M
- Earnings Per Share (EPS)
- 2.72
Cash Flow
In the last 12 months, operating cash flow was -241.54M and capital expenditures -4.96M, giving a free cash flow of -246.50M billion.
- Operating Cash Flow
- -241.54M
- Free Cash Flow
- -246.50M
- Free Cash Flow per Share
- -1.49
Dividends & Yields
Novavax pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.97%
- Earnings Yield
- -4.66%
Stock Price Statistics
- Beta
- 1.51
- 52-Week Price Change
- 45.20%
- 50-Day Moving Average
- 9.34
- 200-Day Moving Average
- 8.08
- Relative Strength Index (RSI)
- 48.43
- Average Volume (3m)
- 3,444
Important Dates
Novavax upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Novavax as a current ratio of 2.13, with Debt / Equity ratio of -194.76%
- Current Ratio
- 2.13
- Quick Ratio
- 2.10
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- 0.02
- Interest Coverage Ratio
- 24.98
Taxes
In the past 12 months, Novavax has paid 1.86M in taxes.
- Income Tax
- 1.86M
- Effective Tax Rate
- 0.00
Enterprise Valuation
Novavax EV to EBITDA ratio is -47.91, with an EV/FCF ratio of -6.96.
- EV to Sales
- 4.17
- EV to EBITDA
- -47.91
- EV to Free Cash Flow
- -6.96
- EV to Operating Cash Flow
- -7.11
Balance Sheet
Novavax has EUR 622.36M in cash and marketable securities with EUR 292.09M in debt, giving a net cash position of EUR 330.27M billion.
- Cash & Marketable Securities
- EUR 622.36M
- Total Debt
- EUR 292.09M
- Net Cash
- EUR 330.27M
- Net Cash Per Share
- EUR 2.00
- Tangible Book Value Per Share
- -EUR 1.99
Margins
Gross margin is 77.25%, with operating margin of -19.58%, and net profit margin of -18.64%.
- Gross Margin
- 77.25%
- Operating Margin
- -19.58%
- Pretax Margin
- -17.47%
- Net Profit Margin
- -18.64%
- EBITDA Margin
- -8.70%
- EBIT Margin
- -12.17%
Analyst Forecast
The average price target for Novavax is EUR 12.13, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 12.13
- Price Target Upside
- 34.35% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 5
- Revenue Growth Forecast
- -64.18%
- EPS Growth Forecast
- -119.12%
Scores
- Smart Score
- 10
- AI Score
- ―
